JP2019529566A5 - - Google Patents

Download PDF

Info

Publication number
JP2019529566A5
JP2019529566A5 JP2019538108A JP2019538108A JP2019529566A5 JP 2019529566 A5 JP2019529566 A5 JP 2019529566A5 JP 2019538108 A JP2019538108 A JP 2019538108A JP 2019538108 A JP2019538108 A JP 2019538108A JP 2019529566 A5 JP2019529566 A5 JP 2019529566A5
Authority
JP
Japan
Prior art keywords
ubenimex
administered
medicament
inhibitor
agonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019538108A
Other languages
English (en)
Japanese (ja)
Other versions
JP7022136B2 (ja
JP2019529566A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/054087 external-priority patent/WO2018064373A1/en
Publication of JP2019529566A publication Critical patent/JP2019529566A/ja
Publication of JP2019529566A5 publication Critical patent/JP2019529566A5/ja
Application granted granted Critical
Publication of JP7022136B2 publication Critical patent/JP7022136B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019538108A 2016-09-28 2017-09-28 非アルコール性脂肪性肝炎の治療のための方法及び医薬組成物 Expired - Fee Related JP7022136B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662400963P 2016-09-28 2016-09-28
US62/400,963 2016-09-28
US201762460606P 2017-02-17 2017-02-17
US62/460,606 2017-02-17
US201762469722P 2017-03-10 2017-03-10
US62/469,722 2017-03-10
PCT/US2017/054087 WO2018064373A1 (en) 2016-09-28 2017-09-28 Methods and pharmaceutical compositions for the treatment of non-alcoholic steatohepatitis

Publications (3)

Publication Number Publication Date
JP2019529566A JP2019529566A (ja) 2019-10-17
JP2019529566A5 true JP2019529566A5 (enExample) 2020-07-02
JP7022136B2 JP7022136B2 (ja) 2022-02-17

Family

ID=61760848

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019538108A Expired - Fee Related JP7022136B2 (ja) 2016-09-28 2017-09-28 非アルコール性脂肪性肝炎の治療のための方法及び医薬組成物

Country Status (6)

Country Link
US (2) US10588880B2 (enExample)
EP (1) EP3518918A4 (enExample)
JP (1) JP7022136B2 (enExample)
KR (1) KR102399254B1 (enExample)
CN (1) CN109862888B (enExample)
WO (1) WO2018064373A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109862888B (zh) 2016-09-28 2022-08-12 艾格尔峰生物制药有限公司 用于治疗非酒精性脂肪性肝炎的方法和药物组合物
CA3082178A1 (en) * 2017-11-28 2019-06-06 Eiger Biopharmaceuticals, Inc. Methods and pharmaceutical compositions for the treatment of non-alcoholic steatohepatitis
US10806735B2 (en) * 2018-04-24 2020-10-20 Ph Pharma Co., Ltd. Use of neutrophil elastase inhibitors in liver disease
EP3811937A1 (en) * 2019-10-24 2021-04-28 Sorbonne Universite Compounds for use in the prevention and/or treatment of non-alcoholic fatty liver disease
US11478533B2 (en) 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine
CA3221177A1 (en) 2021-11-01 2023-05-04 Meghan Kerrisk Campbell Benzodioxane modulators of leukotriene a4 hydrolase (lta4h) for prevention and treatment of aging-associated diseases

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4052449A (en) 1974-07-01 1977-10-04 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Biologically active substance, bestatin, and production thereof
US4029547A (en) 1974-07-01 1977-06-14 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Biologically active substance, bestatin, and production thereof
JPH0759507B2 (ja) * 1989-02-23 1995-06-28 日本化薬株式会社 骨髄異形成症候群治療剤
CN1098249C (zh) * 1995-06-21 2003-01-08 国家医药管理局四川抗菌素工业研究所 乌比美克及含乌比美克的药物组合物治疗病毒性肝炎的用途
US20080025986A1 (en) 2003-06-06 2008-01-31 Ozes Osman N Methods of Treating Tnf-Mediated Disorders
RU2419430C2 (ru) * 2006-02-09 2011-05-27 Дайити Санкио Компани, Лимитед Противораковая фармацевтическая композиция
JP2009109426A (ja) * 2007-10-31 2009-05-21 Sysmex Corp 検体前処理液、ウイルス測定用キット及びウイルス検出方法
WO2012071459A1 (en) 2010-11-22 2012-05-31 The Regents Of The University Of California New indication for use of niacin (nicotinic acid) for treatment, prevention and reversal of fatty liver disease
US8962687B2 (en) 2012-12-05 2015-02-24 Medicinova, Inc. Method of treating liver disorders
US9233089B2 (en) 2012-03-23 2016-01-12 The Board Of Trustees Of The Leland Stanford Junior University Treatment of pulmonary hypertension with leukotriene inhibitors
CA2819967C (en) 2012-08-31 2016-03-22 Intermune, Inc. Use of pirfenidone concomitantly with ciprofloxacin
EP4215205A1 (en) * 2013-01-03 2023-07-26 Oramed Ltd. Methods and compositions for treating nafld, hepatic steatosis, and sequelae thereof
DK3043865T3 (da) * 2013-09-11 2021-02-01 Univ Claude Bernard Lyon Fremgangsmåder og farmaceutiske sammensætningr til behandlingen af hepatitis b-virusinfektion
US20150111878A1 (en) * 2013-10-22 2015-04-23 Steven Hoffman Compositions and methods for treating intestinal hyperpermeability
ES2732845T3 (es) * 2013-12-04 2019-11-26 Galmed Res & Development Ltd Sales de Aramchol
WO2016149126A1 (en) 2015-03-13 2016-09-22 The Board Of Trustees Of The Leland Stanford Junior University Ltb4 inhibition to prevent and treat human lymphedema
CN104784178B (zh) * 2015-05-08 2017-04-12 重庆医科大学 尼克酰胺作为有效成分在制备乙型肝炎治疗药物中的用途
CN104887655A (zh) * 2015-06-12 2015-09-09 上海来益生物药物研究开发中心有限责任公司 乌苯美司在制备用于预防和治疗炎症疾病和与炎症相关的感染疾病的药物制剂中的应用
EP3370703A4 (en) 2015-11-06 2019-06-19 Gemphire Therapeutics Inc. GEMCABEN COMBINATIONS FOR TREATING HEART CIRCULATION DISEASES
CN109862888B (zh) 2016-09-28 2022-08-12 艾格尔峰生物制药有限公司 用于治疗非酒精性脂肪性肝炎的方法和药物组合物
CA3082178A1 (en) 2017-11-28 2019-06-06 Eiger Biopharmaceuticals, Inc. Methods and pharmaceutical compositions for the treatment of non-alcoholic steatohepatitis

Similar Documents

Publication Publication Date Title
JP2019529566A5 (enExample)
ATE350040T1 (de) Stabilisierte pharmazeutische zusammensetzung enthaltend einen nichtsteroiden entzündungshemmenden wirkstoff und prostaglandin
CA2956257C (en) Combination treatment of sglt2 inhibitors and dopamine agonists for preventing metabolic disorders in equine animals
ES2767084T3 (es) Nuevo uso
CA2568443A1 (en) Multi-layer tablet comprising non-steroidal anti-inflammatory drugs, decongestants and non-sedating antihistamines
HRP20160189T1 (hr) Liječenje crohnove bolesti lakvinimodom
JP2015038135A5 (enExample)
HRP20150644T1 (hr) Metoda za lijeäśenje atrijalne fibrilacije
EP2797584B1 (en) Combinations of diacerein and non-steroidal inflammation drugs
RU2008121767A (ru) Пероральная фармацевтическая лекарственная форма, содержащая в качестве активных ингредиентов ингибитор протонного насоса совместно с ацетилсалициловой кислотой
US7303761B2 (en) Stabilised pharmaceutical composition comprising an extended release non-steroidal anti-inflammatory agent and an immediate release prostaglandin
HRP20211826T1 (hr) Čvrste farmaceutske kompozicije koje sadrže inhibitor integraze
BG102669A (bg) Метод за лечение и фармацевтичен състав
Kaur et al. Diacerein, its beneficial impact on chondrocytes and notable new clinical applications
WO2012173581A1 (en) Thiocolchicoside, etodolac and famotidine combinations
IL274414B2 (en) Oral rifamycin sv compositions
JP2019218379A5 (enExample)
JP2020523334A5 (enExample)
JPWO2020257671A5 (enExample)
JP2021504479A5 (enExample)
CN100502870C (zh) 含有瑞舒伐他汀或匹伐他汀和b族维生素的药物组合物
ECSP10010054A (es) Composiciones farmacéuticas que comprenden la combinación de un agente antiinflamatorio no esteroideo y un agente inhibidor de la xantino oxidasa útiles para el control y tratamiento de la gota, artritis gotosa y enfermedades relacionadas
US11648240B2 (en) Pharmaceutical composition comprising famotidine, lidocaine and melatonin
WO2018004498A1 (en) Nsaid and h2 receptor antagonist combinations for the treatment of pain and inflammation
JP2007513095A5 (enExample)